Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

Autor: Jan Gryczynski, Lisa A. Marsch, Keith Goldfeld, Mia Malone, Robert P. Schwartz, Wendy Martin, Laura B. Monico, Kathleen Bell, Rusty Reeves, Kasey Talon, Anna Cheng, Joshua D. Lee, Amesika N. Nyaku, Sandra Violette, David Farabee, Randy Torralva, Nicole Beckwith, Sandra A. Springer, Jennifer P. Wisdom, Elizabeth Needham Waddell, Kasey Harding, Ryan McDonald, Elizabeth C. Saunders, Andrew Suchocki, Thomas Groblewski
Rok vydání: 2021
Předmět:
Zdroj: J Subst Abuse Treat
ISSN: 0740-5472
DOI: 10.1016/j.jsat.2021.108389
Popis: The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.
Databáze: OpenAIRE